Data exclusivity will extend pharma monopolies, delay access to affordable medicines, activists say

In a letter to the Health, Commerce Ministries, activists say India has no global obligation to accept data exclusivity; warn that it will stop the use of existing clinical trial data, harm India’s generics industry

​In a letter to the Health, Commerce Ministries, activists say India has no global obligation to accept data exclusivity; warn that it will stop the use of existing clinical trial data, harm India’s generics industry